DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-647/S-016

King Pharmaceuticals, Inc.
Attention: Mr. Tom W. Der
501 Fifth Street
Bristol, TN 37620

Dear Mr. Der:

Please refer to your supplemental new drug application dated May 3, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Corzide (nadolol and bendroflumethiazide) 40/5 & 80/5 mg Tablets.

We acknowledge receipt of your submissions dated December 5, 2002 and May 13, 2003.

Your submission of May 13, 2003 constituted a complete response to our November 22, 2002 action letter.

This supplemental new drug application provides for final printed labeling (FPL) revised as follows:

1. The following subsection has been added to the end of the **PRECAUTIONS** section:

   Geriatric Use

   Clinical studies of Corzide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reaction to this drug may be greater in patients with impaired function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

The following additional changes were noted:

1. The following paragraph in the **INDICATIONS** section was changed from bold type in the previous labeling to regular type:

   This fixed combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components.

2. The following changes have been made in the **HOW SUPPLIED** section:

- **40 mg nadolol combined with 5 mg bendroflumethiazide** in bottles of 100 tablets (NDC 0003-0283-50)
- **80 mg nadolol combined with 5 mg bendroflumethiazide** in bottles of 100 tablets (NDC 0003-0284-50)

To:

- **40 mg nadolol combined with 5 mg bendroflumethiazide** in bottles of 100 tablets (NDC 61570-175-01)
- **80 mg nadolol combined with 5 mg bendroflumethiazide** in bottles of 100 tablets (NDC 61570-176-01)

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling submitted on May 13, 2003.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

{See appended electronic signature page}

Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Doug Throckmorton

5/30/03 01:40:53 PM